<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

CU Cancer Center News and Stories

lymphoma

Research    Awards    lymphoma

Rosemary Rochford, PhD, Receives Henle Award for Decades of Research on Epstein-Barr Virus-Related Cancer

University of Colorado Cancer Center member Rosemary Rochford, PhD, has spent the past 34 years researching the Epstein-Barr virus (EBV) a virus that causes several types of cancer, including Burkitt lymphoma, nasopharyngeal carcinoma, gastric carcinoma, Hodgkin’s disease, and non-Hodgkin’s lymphoma. 


Author Greg Glasgow | Publish Date April 25, 2024
Full Story

Research    lymphoma

CU Cancer Center Members Spotlight New Treatments for Relapsed Lymphomas

A prestigious invitation to chair an educational program session at the annual meeting of the American Society of Hematology (ASH) in December 2023 offered University of Colorado Cancer Center member Manali Kamdar, MD, an opportunity to update the profession about two increasingly common treatments for relapsed lymphomas.


Author Greg Glasgow | Publish Date March 11, 2024
Full Story

Patient Care    Community    Immunotherapy    lymphoma    ColoradoSPH at CU Anschutz   

CU Cancer Center Member Gains Unique Perspective as Cancer Patient

For a significant portion of his career, Arnold Levinson, PhD, MJ, has done work related to cancer.


Author Rachel Sauer | Publish Date June 16, 2023
Full Story

Research    Blood Cancer    Immunotherapy    lymphoma

What is the Best Lymphoma Treatment After CAR T Therapy Fails? 

For 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend. Typically given to lymphoma patients for whom other treatments have proven ineffective, CAR T therapy involves removing immune cells from the body via a blood draw, reengineering them to become better cancer fighters, then reintroducing them to the bloodstream, where they seek out and destroy cancer cells. 


Author Greg Glasgow | Publish Date April 25, 2023
Full Story

Research    Immunotherapy    lymphoma

Research Shows CAR T Cell Therapy Is Effective Second-Line Treatment for Large B-Cell Lymphoma

Large B-cell lymphoma (LBCL) is one of the most aggressive lymphomas and accounts for about 30% of all lymphoma diagnoses.


Author Rachel Sauer | Publish Date July 14, 2022
Full Story

CU Cancer Center In the News

News Medical

Study shows effectiveness of treating pancreatic cancer patients with chemotherapy before surgery

news outletNews Medical
Publish DateJune 19, 2024

A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.

Full Story
Cancer Network

Liso-cel May Show Benefit in Earlier Therapy Lines for Lymphoma Subgroups

news outletCancer Network
Publish DateJune 14, 2024

In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.

Full Story
Cancer Health

2024 Cancer Health 25: People Who Power Clinical Trials

news outletCancer Health
Publish DateJune 11, 2024

This year's Cancer Health 25 highlights the transformative power and promise of clinical trials. University of Colorado Cancer Center member Jessica McDermott, MD, MSCS, is leading clinical trials at both the CU Cancer Center and the Rocky Mountain Regional Veterans Affairs Medical Center. Additionally, she serves as the CU Cancer Center's deputy associate director for diversity and inclusion in clinical research.

Full Story
Cancer Network

Learning to “Aim High” Within Male-Dominated Fields in Public Health

news outletCancer Network
Publish DateJune 10, 2024

Cathy Bradley, PhD, deputy director of the University of Colorado Cancer Center and dean of the Colorado School of Public Health, is a trailblazer in health economics. At a Breaking Barriers: Women in Oncology discussion, she shared insights on overcoming challenges as a woman in a male-dominated field and discussed her research on the impact of employment on cancer patients' health insurance decisions.

Full Story